Tango Therapeutics is a biotechnology startup focused on developing innovative cancer treatments. The company leverages the principle of synthetic lethality, a concept where two genes interact in a way that the loss of both leads to cell death, but the loss of just one does not. This approach allows Tango to create medicines that specifically target and kill cancer cells while sparing healthy ones.

Tango Therapeutics operates in the oncology market, which involves the study and treatment of tumors. Their primary clients are healthcare providers, including hospitals and specialized cancer treatment centers, as well as pharmaceutical companies looking for cutting-edge cancer therapies.

The business model of Tango Therapeutics revolves around research and development (R&D) of new cancer drugs. They collaborate with larger pharmaceutical companies, such as Gilead Sciences, to co-develop these therapies. This collaboration not only provides financial support but also accelerates the development and commercialization of their treatments. Tango Therapeutics generates revenue through these partnerships, as well as through funding rounds, such as their recent $60 million Series B financing.

Tango's robust pipeline of therapies is backed by a passionate team and bold leadership, including notable appointments like Reid Huber, PhD, and Malte Peters, MD, to their Board of Directors. These strategic moves strengthen their executive team and enhance their capability to bring next-generation targeted immunotherapies to market.

In summary, Tango Therapeutics is a pioneering biotech firm dedicated to creating genetically targeted cancer treatments through strategic collaborations and a strong focus on R&D.

Keywords: biotechnology, cancer treatment, synthetic lethality, oncology, R&D, partnerships, immunotherapy, healthcare, pharmaceuticals, innovation.